TP53 and colorectal carcinoma: Grassilli et al. (29) reported that GSK3B induced resistance to the necrotizing effect of certain antitumor drugs in p53-deficient colorectal cancer (CRC) cells whereas GSK3B knockdown had the opposite effect.